Abstract
Biologics provide a variety of safe and effective treatment options for psoriasis. Crucial players in pathogenesis of psoriasis include cytokines, i.e. IL-17 and IL-23. The systemic drugs ixekizumab and Risankizumab are monoclonal antibodies targeting IL-17A and IL-23A, respectively. Multiple clinical trials evaluated safety and efficacy of these drugs, however real-life data and direct comparisons of clinical data from both drugs remain scarce. Here, we aim to assess the clinical response of 30 patients either treated with ixekizumab or risankizumab over 52 weeks.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
